Jordan Axelrad, MD, MPH

Jordan E. Axelrad, MD, MPH, is the Director of Research in the Inflammatory Bowel Disease Center at NYU Langone Health, and an Associate Professor of Medicine in the Division of Gastroenterology, Department of Medicine, at NYU Grossman School of Medicine. Dr. Axelrad also directs the Clostridioides difficile program. He received his medical and public health degrees from Tufts University School of Medicine. He completed his internal medicine training at the Icahn School of Medicine at Mount Sinai and went on to complete fellowship training in gastroenterology at Columbia University Medical Center, serving as chief fellow. Dr. Axelrad received specialized training in clinical and translational IBD investigation, and his research in areas such as environmental factors in IBD, and in malignant and infectious complications of IBD, has been published and presented internationally. Dr. Axelrad is a member of multiple international gastrointestinal societies, is involved in IBD guideline development and educational programs, and serves on the editorial board of multiple journals. He is the principal investigator of the institutional NYU IBD biorepository, multiple clinical trials and international registries, and mentors trainees in various research activities. His current research is funded by the Crohn’s and Colitis Foundation, the Judith and Stewart Colton Center for Autoimmunity, the New York Crohn's and Colitis Organization, and the National Institutes of Health, and focuses on IBD epidemiology, triggers of IBD onset and flare, recurrent Clostridioides difficile, and models for predicting responsiveness to IBD therapies.
Financial relationships
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:AdisoTopic:IBD, C.difficileDate added:08/09/2023Date updated:08/09/2023
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:AbbvieTopic:IBDDate added:08/09/2023Date updated:08/09/2023
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:BMSTopic:IBDDate added:08/09/2023Date updated:08/09/2023
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:JanssenTopic:IBDDate added:08/09/2023Date updated:08/09/2023
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:PfizerTopic:IBDDate added:08/09/2023Date updated:08/09/2023
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:FreseniusTopic:IBDDate added:08/09/2023Date updated:08/09/2023Relationship end date:03/01/2023
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:BioFire DiagnosticsTopic:C.difficileDate added:08/09/2023Date updated:08/09/2023
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:GenentechTopic:IBDDate added:08/09/2023Date updated:08/09/2023
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:BioFire DiagnosticsTopic:C.difficileDate added:08/09/2023Date updated:08/09/2023
**Disclaimer**
This Continuing Medical Education (CME) Learning Management System, Ethos, includes individuals designated as 'faculty' for CME purposes. Please note that the term 'faculty' refers solely to their role as a contributor/planner within a CME activity and does not imply any formal affiliation with UT Southwestern Medical Center (UTSW). The display of names and credentials is intended for educational purposes only and does not necessarily indicate a professional or academic relationship with UTSW. Participants are encouraged to verify the affiliations and credentials of faculty members independently if further clarification is needed.

Facebook
X
LinkedIn
Forward